Skip to content

Real-world research and clinical prediction model establishment of Fuzheng Differentiation and Treatment for the prevention of postoperative recurrence and metastasis of stage IIIA non-small cell lung cancer

Real-world research and clinical prediction model establishment of Fuzheng Differentiation and Treatment for the prevention of postoperative recurrence and metastasis of stage IIIA non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072619
Enrollment
Unknown
Registered
2023-06-19
Start date
2022-06-30
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IIIA post-operative non-small cell lung cancer

Interventions

Adjuvant chemotherapy±radiotherapy combined with Fuzheng Differentiation Method herbal treatment group:N/A
Adjuvant chemotherapy ± radiotherapy group:N/A

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with stage IIIA non-small cell lung cancer who underwent radical surgery. 2. Within 3 months after completion of postoperative adjuvant chemotherapy (patients with IIIA-N2 can receive postoperative adjuvant radiotherapy), and without recurrence or metastasis. 3. Chinese medicine identification as Qi deficiency, Yin deficiency or both Qi and Yin deficiency type. 4. Age between 18 and 75 years old (including 18 and 75 years old). 5. Physical status score (ECOG PS) = 3. 6. Those with normal blood count, liver and kidney function.

Exclusion criteria

Exclusion criteria: 1. Those with expected survival <6 months. 2. Patients without a clear pathological diagnosis. 3. Patients with combined serious diseases of the heart, liver, kidney and hematopoietic system. 4. Patients who are pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
disease-free survival(DFS);

Secondary

MeasureTime frame
1-year, 2-year, 3-year disease-free survival rate(DFSR);Tumor markers (CEA);

Countries

China

Contacts

Public ContactRUOYAN QIN

Longhua Hospital of Shanghia University of Traditional Chinese Medicine

2362419852@qq.com+86 64385700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026